REPORTS

Let’s Pullulate and Expand Your Business

Bispecific Antibody Market - Global Professional Analysis and Forecast to 2026

Oct 16, 2019  |  141 PAGES  |  REPORT CODE: CMM213113
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Bispecific Antibody market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 7.4% during the forecast period.

This report presents the market size and development trends by detailing the Bispecific Antibody market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Bispecific Antibody market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Bispecific Antibody industry and will help you to build a panoramic view of the industrial development.

Bispecific Antibody Market, By Type:

  • Catumaxomab (Removab)

  • Blinatumomab

  • Duligotumab

  • SAR 156597

Bispecific Antibody Market, By Application:

  • BsMAb for Diagnosis of Infectious Diseases

  • Diagnosis of Bacterial Infections

  • Diagnosis of Viral Infections

  • BsMAb for Cancer Diagnostic

  • BsAbs Blocking Signaling Pathways

  • BsAbs Targeting Tumor Angiogenesis

  • Specific Delivery of Effector Compounds to Targets

  • Bispecific Antibodies & Gene Therapy

Some of the leading players are as follows:

  • Amgen

  • NovImmune SA

  • OncoMed Pharmaceuticals

  • AstraZeneca (MedImmune)

  • Immunomedics

  • Eli Lilly

  • Jounce Therapeutics

  • Pieris

  • Affimed Therapeutics

  • Merus

  • Ablynx

  • MacroGenics

  • Neovii Biotech

  • Regeneron Pharmaceuticals

  • Genmab

  • EMD Serono

  • Adimab

  • Emergent BioSolutions

  • Sanofi

  • Genentech

  • Roche

  • Chugai Pharmaceutical

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Bispecific Antibody Market: Technology Type Analysis

  • 4.1 Bispecific Antibody Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Bispecific Antibody Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Catumaxomab (Removab)

    • 4.3.2 Blinatumomab

    • 4.3.3 Duligotumab

    • 4.3.4 SAR 156597

5 Bispecific Antibody Market: Product Analysis

  • 5.1 Bispecific Antibody Product Market Share Analysis, 2018 & 2026

  • 5.2 Bispecific Antibody Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Bispecific Antibody Market: Application Analysis

  • 6.1 Bispecific Antibody Application Market Share Analysis, 2018 & 2026

  • 6.2 Bispecific Antibody Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 BsMAb for Diagnosis of Infectious Diseases

    • 6.3.2 Diagnosis of Bacterial Infections

    • 6.3.3 Diagnosis of Viral Infections

    • 6.3.4 BsMAb for Cancer Diagnostic

    • 6.3.5 BsAbs Blocking Signaling Pathways

    • 6.3.6 BsAbs Targeting Tumor Angiogenesis

    • 6.3.7 Specific Delivery of Effector Compounds to Targets

    • 6.3.8 Bispecific Antibodies & Gene Therapy

7 Bispecific Antibody Market: Regional Analysis

  • 7.1 Bispecific Antibody Regional Market Share Analysis, 2018 & 2026

  • 7.2 Bispecific Antibody Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Amgen

    • 9.1.1 Amgen Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 NovImmune SA

    • 9.2.1 NovImmune SA Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 OncoMed Pharmaceuticals

    • 9.3.1 OncoMed Pharmaceuticals Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 AstraZeneca (MedImmune)

    • 9.4.1 AstraZeneca (MedImmune) Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Immunomedics

    • 9.5.1 Immunomedics Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Eli Lilly

    • 9.6.1 Eli Lilly Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Jounce Therapeutics

    • 9.7.1 Jounce Therapeutics Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Pieris

    • 9.8.1 Pieris Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Affimed Therapeutics

    • 9.9.1 Affimed Therapeutics Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Merus

    • 9.10.1 Merus Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Ablynx

    • 9.11.1 Ablynx Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 MacroGenics

    • 9.12.1 MacroGenics Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Neovii Biotech

    • 9.13.1 Neovii Biotech Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Regeneron Pharmaceuticals

    • 9.14.1 Regeneron Pharmaceuticals Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 Genmab

    • 9.15.1 Genmab Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

  • 9.16 EMD Serono

    • 9.16.1 EMD Serono Company overview

    • 9.16.2 Financial performance

    • 9.16.3 Product benchmarking

    • 9.16.4 Strategic initiatives

    • 9.16.5 SWOT analysis

  • 9.17 Adimab

    • 9.17.1 Adimab Company overview

    • 9.17.2 Financial performance

    • 9.17.3 Product benchmarking

    • 9.17.4 Strategic initiatives

    • 9.17.5 SWOT analysis

  • 9.18 Emergent BioSolutions

    • 9.18.1 Emergent BioSolutions Company overview

    • 9.18.2 Financial performance

    • 9.18.3 Product benchmarking

    • 9.18.4 Strategic initiatives

    • 9.18.5 SWOT analysis

  • 9.19 Sanofi

    • 9.19.1 Sanofi Company overview

    • 9.19.2 Financial performance

    • 9.19.3 Product benchmarking

    • 9.19.4 Strategic initiatives

    • 9.19.5 SWOT analysis

  • 9.20 Genentech

    • 9.20.1 Genentech Company overview

    • 9.20.2 Financial performance

    • 9.20.3 Product benchmarking

    • 9.20.4 Strategic initiatives

    • 9.20.5 SWOT analysis

  • 9.21 Roche

    • 9.21.1 Roche Company overview

    • 9.21.2 Financial performance

    • 9.21.3 Product benchmarking

    • 9.21.4 Strategic initiatives

    • 9.21.5 SWOT analysis

  • 9.22 Chugai Pharmaceutical

    • 9.22.1 Chugai Pharmaceutical Company overview

    • 9.22.2 Financial performance

    • 9.22.3 Product benchmarking

    • 9.22.4 Strategic initiatives

    • 9.22.5 SWOT analysis

 

The List of Tables and Figures (Totals 109 Figures and 133 Tables)

  • Figure Catumaxomab (Removab) Bispecific Antibody market, 2015 - 2026 (USD Million)

  • Figure Blinatumomab Bispecific Antibody market, 2015 - 2026 (USD Million)

  • Figure Duligotumab Bispecific Antibody market, 2015 - 2026 (USD Million)

  • Figure SAR 156597 Bispecific Antibody market, 2015 - 2026 (USD Million)

  • Figure BsMAb for Diagnosis of Infectious Diseases market, 2015 - 2026 (USD Million)

  • Figure Diagnosis of Bacterial Infections market, 2015 - 2026 (USD Million)

  • Figure Diagnosis of Viral Infections market, 2015 - 2026 (USD Million)

  • Figure BsMAb for Cancer Diagnostic market, 2015 - 2026 (USD Million)

  • Figure BsAbs Blocking Signaling Pathways market, 2015 - 2026 (USD Million)

  • Figure BsAbs Targeting Tumor Angiogenesis market, 2015 - 2026 (USD Million)

  • Figure Specific Delivery of Effector Compounds to Targets market, 2015 - 2026 (USD Million)

  • Figure Bispecific Antibodies & Gene Therapy market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Bispecific Antibody market, by country, 2015 - 2026 (USD Million)

  • Table North America Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table North America Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table North America Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table Canada Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table Canada Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Europe Bispecific Antibody market, by country, 2015 - 2026 (USD Million)

  • Table Europe Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table Europe Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table Europe Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table Germany Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table Germany Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table France Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table France Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table Italy Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table Italy Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table Spain Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table Spain Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Bispecific Antibody market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table China Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table China Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table Japan Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table Japan Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table India Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table India Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Bispecific Antibody market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table MEA Bispecific Antibody market, by country, 2015 - 2026 (USD Million)

  • Table MEA Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table MEA Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table MEA Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Bispecific Antibody market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Bispecific Antibody market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Bispecific Antibody market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Amgen Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table NovImmune SA Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table OncoMed Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AstraZeneca (MedImmune) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Immunomedics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eli Lilly Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Jounce Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pieris Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Affimed Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Merus Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Ablynx Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table MacroGenics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Neovii Biotech Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Regeneron Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Genmab Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table EMD Serono Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Adimab Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Emergent BioSolutions Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Genentech Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Roche Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Chugai Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$4840
$9680
BUY NOWClick MeBUY NOW
top